---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030102"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:21:44.493910+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M

## Summary
- Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.
- Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.
- Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).
- Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.
- Gross profit margin stable at 62%; operating expenses down ~14% YoY.

## SEC filing metadata
- accession: 0001493152-24-030102
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/0001493152-24-030102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315224030102/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030102
- JSON: https://secwatch.observer/filing/0001493152-24-030102.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.